During a median duration of @ years , the primary end point occurred in @ patients in the darapladib group and @ in the placebo group ( @ % vs @ % at @ years ; hazard ratio -LSB- HR -RSB- , @ -LSB- @ % CI , @-@ @ -RSB- ; P = @ ) .